Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Are you still there?

Due to inactivity, you will be signed out in two minutes unless
you click 'Continue'.

Panel:   ARBank custom (n=29) (Custom)
AR Bank # 0591 Escherichia coli
Study ID: FPZ-01

Biosample Accession #: SAMN11953911

Panel:  Cefepime/ zidebactam (FPZ)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin >64R
Ampicillin >32R
Ampicillin/sulbactam 1>32R
Aztreonam >64R
Cefazolin >8R
Cefepime >32R
Cefepime/zidebactam 20.25---
Cefotaxime >64R
Cefotaxime/clavulanic acid 1 58---
Cefoxitin >16R
Ceftazidime >128R
Ceftazidime/avibactam 12S
Ceftazidime/clavulanic acid 1 58---
Ceftolozane/tazobactam 1>16R
Ceftriaxone >32R
Ciprofloxacin >8R
Colistin 0.5I
Doripenem S
Ertapenem 1I
Gentamicin >16R
Imipenem <=0.5S
Imipenem/relebactam 10.06---
Imipenem+chelators 4<=0.25---
Levofloxacin >8R
Meropenem <=0.12S
Piperacillin/tazobactam 132I
Tetracycline >32R
Tigecycline 3<=0.5S
Tobramycin >16R
Trimethoprim/sulfamethoxazole 1<=0.5S
Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
S – I –R Interpretation (INT) derived from CLSI 2020 M100 S30
1 Reflects MIC of first component
2 Cefepime to zidebactam ratio (1:1)
3 Based on FDA break points
4 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
5 Screen test for Extended-Spectrum-β-lactamase (ESBL) production (CLSI M100). Per CLSI, use of the ESBL test is limited to isolates of Klebsiella pneumoniae, K. oxytoca, Escherichia coli, and Proteus mirabilis. It should be noted that the presence of other β-lactamases (carbapenemases and/or AmpC) or porin alterations can mask the ESBL production and confound the interpretation of the ESBL screen test.
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
CategoryGene
Aminoglycoside aadA1, ant(2")-la, rmtB
Beta-lactam CTX-M-15
Macrolide-Lincosamide-Streptogramin mph(A)
Phenicols/Bicyclomycins cmlA6
Quinolone qepA1
Sulfonamides sul1
Tetracyclines tet(B)
 
Disclaimer:
No disclaimer.
Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE
Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)
Open vial aseptically to avoid contamination
Using a sterile loop, remove a small amount of frozen isolate from the top of the vial
Aseptically transfer the loop to BAP
Use streak plate method to isolate single colonies
Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.
Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.



Disclaimer:

Isolate History
Date Action Performed
08/11/22Gene was added
08/11/22Category was added
08/11/22Gene was added
08/11/22Category was added
10/25/18New Isolate added to panel
Top of Page
TOP